Results 51 to 60 of about 734,803 (234)
Cervical cancer prevention by vaccination: review
Frontiers in OncologyRoutine use of human papillomavirus (HPV) vaccines is recommended in adolescents under 15 years of age worldwide. Still, effective programs remain suboptimal for several factors, making the WHO strategy to eradicate cervical cancer public health with an ...
Julio Cesar González-Rodríguez +2 more
doaj +1 more source
International Journal of Cancer, EarlyView.What's New? Effective cervical cancer prevention centers around screening and testing for human papillomavirus (HPV) infection. With birth cohorts of HPV‐vaccinated women now reaching screening‐eligible ages, however, the best means to maintaining cost‐effective cervical cancer screening is unclear.
Tiago M. de Carvalho +2 more
wiley +1 more source
Journal of Immunological Research, 2015 Background. When the bivalent and the quadrivalent HPV vaccines were marketed they were presented as having comparable efficacy against cervical cancer. Differences between the vaccines are HPV types included and formulation of the adjuvant. Method.
S. Di Mario +5 more
semanticscholar +1 more source
Human Papillomavirus Vaccine Inaccuracies
American Journal of Public Health, 2012 Although Maine et al. provided a comprehensive overview of the state of cervical cancer prevention today,1 their article presented some inaccuracies and tended to downplay the benefits of vaccination and magnified its challenges. For example, the authors failed to acknowledge that immunization has much less socioeconomic variation than screening does ...
Vivien Davis, Tsu, D Scott, LaMontagne
openaire +3 more sources
Papillomavirus-Like Particle Vaccines [PDF]
JNCI Monographs, 2000 Papillomavirus-like particle (VLP)-based subunit vaccines have undergone rapid development over the past 8 years. Three types are being investigated. The most basic type is composed of only the L1 major capsid protein and is designed to prevent genital human papillomavirus (HPV) infection by inducing virus-neutralizing antibodies.
J T, Schiller, D R, Lowy
openaire +2 more sources
International Journal of Cancer, EarlyView.What's New? Cancers of the breast and female genital tract represent more than half of all cancers in women in sub‐Saharan Africa. Here, the authors assessed incidence trends in a female population living in urban sub‐Saharan Africa based on the Zimbabwe National Cancer Registry in Harare over a 30‐year period.
Eric Chokunonga +7 more
wiley +1 more source
Emerging human papillomavirus vaccines [PDF]
Expert Opinion on Emerging Drugs, 2012 Identification of human papillomavirus (HPV) as the etiologic factor of cervical, anogenital, and a subset of head and neck cancers has stimulated the development of preventive and therapeutic HPV vaccines to control HPV-associated malignancies. Excitement has been generated by the commercialization of two preventive L1-based vaccines, which use HPV ...
Barbara, Ma +7 more
openaire +2 more sources
International Journal of Gynecology &Obstetrics, EarlyView.Abstract Objective To evaluate the financial applicability of the DNA‐HPV test for cervical cancer screening in a developing country like Brazil. Methods This was a retrospective, observational study based on documentary data, conducted to assess the cost‐effectiveness of cervical cancer screening strategies in Brazil.
Felipe Polido Urbano +4 more
wiley +1 more source
Vaccine, 2015 Background Detailed cost evaluations of delivery of new vaccines such as pneumococcal conjugate, human papillomavirus (HPV), and rotavirus vaccines in low and middle-income countries are scarce.
F. Ngabo +8 more
semanticscholar +1 more source
npj Vaccines, 2020 We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in ...
F. Mariz +14 more
semanticscholar +1 more source